We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
Read MoreHide Full Article
AstraZeneca (AZN - Free Report) announced a definitive agreement to acquire Fusion Pharmaceuticals (FUSN - Free Report) , which will add next-generation radioconjugates, a promising modality in cancer treatment, to its cancer pipeline.
AstraZeneca has offered to acquire Fusion, a Canadian company, for a price of $21.00 per share in cash, which represents a premium of 97% to the latter’s closing price of $10.64 on Monday, Mar 18. In addition, AstraZeneca will be entitled to make a non-transferable contingent value (CV) payment of $3.00 per share in cash on achievement of a specified regulatory milestone. The upfront cash and CV payment add up to a total transaction value of approximately $2.4 billion.
Fusion makes next-generation radiopharmaceuticals that deliver a radioactive isotope directly to cancer cells through precise targeting using molecules such as antibodies, peptides or small molecules. It has a diversified pipeline of targeted alpha therapy (TAT) programs. These targeted treatments minimize damage to nearby healthy cells and are being seen as potential replacements for traditional regimens like chemotherapy and radiotherapy for treating cancer.
Fusion already has a collaboration with AstraZeneca to jointly develop novel TATs and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Response Inhibitors (DDRis) and immuno-oncology agents.
Fusion’s key clinical-stage pipeline candidate is FPI-2265, a small molecule-based TAT targeting prostate-specific membrane antigen, in phase II studies for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Preliminary data from approximately 20 to 30 patients from the phase II study (TATCIST) on FPI-2265 are expected to be released in April 2024. Target enrollment has been achieved in the study. A phase III registrational study is expected to begin in 2025. Fusion expects to initiate a combination study of FPI-2265 plus Merck (MRK - Free Report) /AstraZeneca’s Lynparza (olaparib) in earlier lines of mCRPC treatment in the first half of 2024.
In the past year, AstraZeneca’s stock has declined 1.4% against the industry’s 30.5% rise.
Image Source: Zacks Investment Research
Fusion is also jointly developing FPI-2068, its novel TAT candidate, which targets solid tumors expressing EGFR-cMET with AstraZeneca under the companies' multi-asset collaboration agreement. Pre-clinical data on the candidate demonstrated strong anti-tumor activity and confirmatory evidence of FPI-2068's mechanism of action. In April 2023, Fusion received FDA clearance to begin clinical development of FPI-2068.
Its other pipeline candidate is FPI-1434, which is in phase I for patients with solid tumors expressing IGF-1R. Fusion Pharmaceuticals has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with the latter’s blockbuster PD-L1 inhibitor, Keytruda, in patients with solid tumors expressing IGF-1R.
Lately, there have been quite a few M&A deals in the pharma and biotech sector. This year, Bristol Myers Squibb (BMY - Free Report) acquired Mirati Therapeutics, an oncology company, and Karuna Therapeutics, which makes drugs for psychiatric and neurological conditions. In the radiopharmaceuticals space, in December 2023, Bristol-Myers said it will acquire clinical-stage radiopharmaceutical therapeutics company RayzeBio for approximately $4.1 billion. Eli Lilly acquired POINT Biopharma, a maker of next-generation radioligand therapies for treating cancers, for approximately $1.4 billion in cash last year.
Image: Bigstock
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
AstraZeneca (AZN - Free Report) announced a definitive agreement to acquire Fusion Pharmaceuticals (FUSN - Free Report) , which will add next-generation radioconjugates, a promising modality in cancer treatment, to its cancer pipeline.
AstraZeneca has offered to acquire Fusion, a Canadian company, for a price of $21.00 per share in cash, which represents a premium of 97% to the latter’s closing price of $10.64 on Monday, Mar 18. In addition, AstraZeneca will be entitled to make a non-transferable contingent value (CV) payment of $3.00 per share in cash on achievement of a specified regulatory milestone. The upfront cash and CV payment add up to a total transaction value of approximately $2.4 billion.
Fusion makes next-generation radiopharmaceuticals that deliver a radioactive isotope directly to cancer cells through precise targeting using molecules such as antibodies, peptides or small molecules. It has a diversified pipeline of targeted alpha therapy (TAT) programs. These targeted treatments minimize damage to nearby healthy cells and are being seen as potential replacements for traditional regimens like chemotherapy and radiotherapy for treating cancer.
Fusion already has a collaboration with AstraZeneca to jointly develop novel TATs and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Response Inhibitors (DDRis) and immuno-oncology agents.
Fusion’s key clinical-stage pipeline candidate is FPI-2265, a small molecule-based TAT targeting prostate-specific membrane antigen, in phase II studies for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Preliminary data from approximately 20 to 30 patients from the phase II study (TATCIST) on FPI-2265 are expected to be released in April 2024. Target enrollment has been achieved in the study. A phase III registrational study is expected to begin in 2025. Fusion expects to initiate a combination study of FPI-2265 plus Merck (MRK - Free Report) /AstraZeneca’s Lynparza (olaparib) in earlier lines of mCRPC treatment in the first half of 2024.
In the past year, AstraZeneca’s stock has declined 1.4% against the industry’s 30.5% rise.
Image Source: Zacks Investment Research
Fusion is also jointly developing FPI-2068, its novel TAT candidate, which targets solid tumors expressing EGFR-cMET with AstraZeneca under the companies' multi-asset collaboration agreement. Pre-clinical data on the candidate demonstrated strong anti-tumor activity and confirmatory evidence of FPI-2068's mechanism of action. In April 2023, Fusion received FDA clearance to begin clinical development of FPI-2068.
Its other pipeline candidate is FPI-1434, which is in phase I for patients with solid tumors expressing IGF-1R. Fusion Pharmaceuticals has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with the latter’s blockbuster PD-L1 inhibitor, Keytruda, in patients with solid tumors expressing IGF-1R.
Lately, there have been quite a few M&A deals in the pharma and biotech sector. This year, Bristol Myers Squibb (BMY - Free Report) acquired Mirati Therapeutics, an oncology company, and Karuna Therapeutics, which makes drugs for psychiatric and neurological conditions. In the radiopharmaceuticals space, in December 2023, Bristol-Myers said it will acquire clinical-stage radiopharmaceutical therapeutics company RayzeBio for approximately $4.1 billion. Eli Lilly acquired POINT Biopharma, a maker of next-generation radioligand therapies for treating cancers, for approximately $1.4 billion in cash last year.
Zacks Rank
Currently, AstraZeneca has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AstraZeneca PLC Price and Consensus
AstraZeneca PLC price-consensus-chart | AstraZeneca PLC Quote